If you already have an account please use the link below to sign in. If you have any problems with your access or would like to request an individual access account please contact our customer service ...
If you already have an account please use the link below to sign in. If you have any problems with your access or would like to request an individual access account please contact our customer service ...
Managing director Frode Lindvik told Norwegian publication Finansavisen that the deal will facilitate Bano's plans to expand abroad, and that the company had a turnover of NOK 331m (€33m) in 2020. The ...
Initial bids for the business were due last week, said one of the sources. Permira already owns Neuraxpharm, a specialty pharma company focused on the treatment of the central nervous system (CNS), ...
At a time when fundraising is slowing down, the firm managed to close its latest fund four months after its launch, the GP said in a statement. Its latest fund is almost 50% larger than its ...
The transaction remains subject to approval from the Dutch healthcare and competition authorities. The company's management team will continue to lead the business, the GP said in a statement. NPM ...
The pan-European and US investor has chosen to reduce its initial target of EUR 6.5bn, settling on a EUR 4.5bn hard-cap, one source said. So far, the GP has secured EUR 4bn in commitments, two sources ...
This is the seventh acquisition for the vehicle, which invests in digital transition and technological innovation for SMEs. The fund held a final close on EUR 200m in December 2022, according to ...
The fund surpassed the record amounts previously raised by the likes of Advent International, Blackstone, Apollo and Hellman and Friedman. The vehicle was launched in January 2023 and surpassed its ...
The exit will generate a gross return on investment of nearly 2.1x money and an IRR of around 27% for Oakley Capital Private Equity III. As part of the transaction, Oakley, via its OriginFund will ...
The GP reaped 6x return on its initial investment and will be reinvesting in the company acquiring a minority stake alongside Anthesis' management team, according to a press release. The deal values ...
The fund held its first close in Q4 2019 towards a target of £350m. Acanthus Advisers is acting as placement agent. British Columbia Investment Management, which is also a direct investor in some of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results